Human Cerebral Blood Flow Regulation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-12

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tests basic differences in how men and women control brain (cerebral) blood flow (CBF), at rest and under stress. The stress is low oxygen or high carbon dioxide. The investigators hypothesize that sex differences per se, plus sex hormone differences, drive different signals in blood vessels that change the way CBF is regulated. The investigators will test these mechanisms with medicine infusions during stress, and measure CBF using state-of-the-art MRI approaches. Research confounding variables like aging and disease will be mitigated by comparing younger adults (18-40 years old).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

NCT03066115

Hypoxia Hypercapnia

WITHDRAWN PHASE1

Mechanisms of Cerebrovascular Control

NCT02936687

Metabolic Syndrome X

COMPLETED PHASE1

Role of Prostaglandins in the Regulation of Brain Blood Flow

NCT00006318

Healthy Hypercapnia

COMPLETED

Effect of Sodium Nitroprusside on Cerebral Blood Flow

NCT03317652

Healthy Male Subjects

COMPLETED NA

Inhaled Nitric Oxide in Brain Injury

NCT03260569

Traumatic Brain Injury

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cerebrovascular disease is the third leading killer in the U.S., and contributes to decreased quality of life and increased long-term care spending. The risk of cerebrovascular disease is inversely associated with resting cerebral blood flow (CBF). Men exhibit a lower resting CBF and have twice the risk of cerebrovascular disease when compared to premenopausal women. The ability of cerebral vessels to respond to challenges is also inversely related to disease risk, and may be useful in identifying at-risk patients pre-clinically. However, these studies are often confounded by aging and/or comorbidities, and the associations provide little insight into physiologic mechanisms responsible for sexually dimorphic cerebrovascular disease risk. Conversely, animal studies use supraphysiologic levels of hormone treatment in primarily young animals, which limits the translational relevance of animal CBF mechanisms. While there is general agreement that estrogen is protective in healthy adults, the basic impact of sex, and physiologic fluctuations in sex hormones, on mechanisms of CBF control remains unclear.

The overall goal of this research program is to investigate the mechanisms which actively control cerebral blood flow (CBF) in humans, particularly how men and women differ in control mechanisms on a regional basis throughout the brain circulation. The investigators propose to study CBF control mechanisms in healthy younger (18-40 yrs) adult men and women. The overall hypothesis is that female sex and sex hormones contribute to larger stress-induced increases in CBF, due to greater prostanoid (COX) and nitric oxide (NOS) dilation.

A key technological innovation of this proposal derives from multi-mode, high-resolution, flow sensitive MRI to quantify CBF at macrovascular and microvascular levels, at rest, and in response to environmental challenges (stress test for the brain). Additionally, the research design allows for quantification of sex differences in two vascular control mechanisms across all brain regions. Preliminary data demonstrate: hypoxic cerebral vasodilation is 60-100% higher in women compared to men, COX inhibition reduces dilation in women but not men, NOS inhibition reduces vasodilation more in women. Those concepts will be tested in Aims 1-2 of the grant in this current proposal, covered in Phase 1 using technical innovative MRI and pharmacologic tools to test potential sex specific mechanisms of CBF control. The conceptual innovation is planned in Aim 3 of the grant (or Phase 2). Participants must complete Phase 1 studies to continue to Phase 2. Study procedures in Phase 1 and 2 are identical, but the investigators conduct them twice: once in the context of sex hormone suppression, and a second time during a single hormone replacement (during suppression), to study the independent impact of testosterone (men) and estrogen (women) on CBF control mechanisms.

Substantial preliminary findings support these hypotheses, and integrated physiologic, pharmacologic, and MRI approaches are available to test them. This state-of-the-art approach will yield previously unattainable insight into not only maintaining basal CBF, but actively controlling it during physiologic demands for increased flow. These novel, high resolution, regionally-specific, sex-specific, and mechanism-specific findings will serve as a knowledge platform, for designing sex-specific CBF studies in high risk disease populations (e.g. diabetes, hypertension, Alzheimer's) which exhibit strong sex-specific etiology and important vascular contributions. To assess the effects of sex hormones on the microbiome, the investigators will also be collecting fecal samples from participants before hormone manipulation, after hormone suppression, and after single hormone add-back.

Three Specific Aims will be addressed in this study:

Aim 1: Test the hypothesis that healthy males exhibit reduced cerebral vasodilation compared to healthy females despite exhibiting similar vasodilation to hypercapnia.

* Aim 1A: Vasodilation to hypoxia will be markedly lower in males, more so in anterior brain regions.
* Aim 1B: Vasodilation to hypercapnia will be similar between sexes.

Aim 2: Test the hypothesis that acute inhibition of COX or NOS will reduce sex differences in hypoxia-mediated cerebral vasodilation.

* Aim 2A: COX-mediates vasodilation primarily in females.
* Aim 2B: NOS mediates vasodilation more in females than males.

Aim 3: Test the hypothesis that manipulating sex steroids can abolish or magnify sex differences in vasodilation.

* Aim 3A: Short-term suppression of sex steroids will abolish sex differences in resting and hypoxic CBF via greater losses of COX- and NOS-mediated vasodilation in females than males.
* Aim 3B: Short-term supplementation of unopposed testosterone in males will magnify sex differences by driving COX vasoconstriction (TXA2) and uncoupled NOS vasoconstriction.
* Aim 3C: Short-term supplementation of unopposed estradiol in females will magnify sex differences via increased NOS and COX vasodilation.

Updated Protocol (CP011):

Fifty-four (54) otherwise healthy adults between 18-40 years of age inclusive composed of 27 males and 27 females. These 54 participants will complete both Aims 1 and 2 (both Aims completed in 2 study visits).

Updated Protocol (CP017):

Fifty-seven (57) otherwise healthy adults between 18-40 years of age inclusive composed of 30 males and 27 females. These 57 participants will complete both Aims 1 and 2 (both Aims completed in 2 study visits). The number of male participants was increased by 3 to meet the recruitment requirements of the Phase 2 (2023-0548) study. Completion of Phase 1 (2020-0336) is required to participate in Phase 2. No females were added as the recruitment for Phase 2 females will fall within the 27 females who will have completed Phase 1 (2020-0336).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Arterial Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Aims 1-2: Both male (n=30) and female (n=27) groups. Participants complete both aims in 2 visits. Participants assigned to one of 2 drug treatments in Aim 2 (n=24/sex/drug). These drugs are mechanistic studies, not treatment studies. Drugs inhibit NOS or COX signaling in blood vessels and are given intravenously during one MRI visit.

Aim 3: Both male (n=20) and female (n=20) groups (a subset of participants enrolled in Aims 1-2) enroll for \~14 days. All 14 days participants suppress endogenous sex hormones with a GnRH agonist/antagonist, and repeat Aim 1-2 visits around days 5-7. Subsequently, males start taking exogenous testosterone, and females take exogenous estrogen for the remaining 7-9 days. On days 12-14 (depending on MRI and participant schedule), participants repeat visits like Aim 1-2. During half those MRI visits, participants will receive one of the two FDA drugs (same as in original Aim 1-2 visit).

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Intervention Type DRUG

Participants will be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Participants will be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.

Participants will be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Participants will be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All participants will be healthy adults between 18-40 years old, matched for age and aerobic fitness
* Participants will be non-hypertensive (\<125/80mm Hg)
* Participants will be non-obese (BMI 19-25 kg/m2)
* Participants will have normal blood glucose (\<100 g/dl)
* Participants will have normal lipids (LDL cholesterol \<130 mg/dl, triglycerides \<150 mg/dl)
* Women must have a natural regular menstrual cycle

Exclusion Criteria

* Participants with a history of:

* peripheral vascular disease
* hepatic disease
* renal disease
* hematologic disease
* stroke
* obesity
* prediabetes
* diabetes
* sleep apnea
* Participants with current BP\>130/85 mmHg
* Regular smokers
* Taking cardiovascular medications
* Women who take hormonal birth control
* Women who are pregnant or have polycystic ovarian syndrome \[Hormonal birth control will not be allowed in women\]
* Contradictions to MRI
* Lactose intolerance

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes